Pink SheetThe Biden Administration’s policies on price inflation rebates in Medicare and Medicaid unintentionally provided President Trump a tool to amplify the threat tariffs would pose to pharma. But Trump’s
Pink SheetJacqueline Corrigan-Curay, acting head of the US Food and Drug Administration’s Center for Drug Evaluation and Research, will retire, allowing Commissioner Martin Makary to fill another influential se
ScripMerck & Co.’s new growth driver Winrevair (sotatercept) appears well positioned for expansion to newly diagnosed individuals with pulmonary arterial hypertension (PAH) based on positive results fr
ScripExelixis may have a steady source of revenue after cabozantinib – approved as Cabometyx and Cometriq – loses market exclusivity, after zanzalintinib delivered positive pivotal Phase III results in col